Affinity Technologies (NASDAQ:BIAF) announced on March 10, 2026, the launch of a large longitudinal clinical study involving 2,000 patients to evaluate the performance of its CyPath® Lung technology ...

Electronic nose breath analysis achieved 80-92% accuracy for detecting lung cancer in patients with suspicious findings. Detection accuracy remained consistent across tumor characteristics, disease ...

LAFAYETTE, La. (KLFY) — Our Lady of Lourdes is now offering patients the latest in lung cancer treatment using AI. The new artificial intelligence-based software and robot-assisted biopsy technology ...

All study participants simultaneously underwent NGS using three sample types: (1) BWF, (2) plasma, and (3) tumor tissue collected during bronchoscopy. The full patient set (FPS) included all enrolled ...

Scientists have created a new low-cost, fast response sensor to detect lung cancer biomarkers, paving the way for the development of screening devices to spot the disease even before symptoms occur.